atcc

Sclareol glycol, a diterpene diol, is utilized as a precursor in the synthesis of ambroxide. It is characterized by a specific stereochemistry at its (3S,6R,8aS)-configurations, with two hydroxyl groups attached at the [2R,3aR,6S,8aR]-octahydro-3a,6,6,8a-tetramethyl-2-(1-methylethyl) perhydrophenanthrene framework.

PF-0463481 is safe and well-tolerated and has the potential for the study of diabetic nephropathy. PF-0463481 is an effective and orally active dual CCR2/CCR5 antagonist. It also has comparable human and rodent CCR2 potency (rat IC50=20.8 nM). PF-0463481

Selinexor (KPT-330) is a small molecule inhibitor of CRM1 with selective and oral activity. Selinexor blocks the cell cycle, induces apoptosis, and has antitumor activity for the treatment of multiple myeloma.

Lanopepden (GSK 1322322) is a potent peptide deformylase inhibitor effective against Staphylococcus aureus strains ATCC 29213 and ATCC 25923, and is applicable in the study of pneumonia, dermatological, and infectious diseases.

1. Octyl Gallate is an antioxidant approved by the US Food and Drug Administration (FDA) as a food additive. 2. Octyl Gallate has antimetastatic activity. 3. Octyl Gallate shows antimicrobial activity against H. pylori, with a minimum inhibitory concentration (MIC) value of 125 ug/mL. 4. Combination therapy with octyl gallate and ferulic acid improves cognition and neurodegeneration in a transgenic mouse model of Alzheimer's disease.5. Octyl Gallate is a potential anticancer agent, it exhibited decreased MCF-7 & MDA-MB-231 survival and induced apoptosis, with IC50 value of 40 uM. 6. Octyl gallate (Octyl 3,4,5-trihydroxybenzoate) has antiviral activity, it shows an inhibitory effect on the growth of herpes simplex virus type 1 (HSV-1) in HEp-2 or Vero cells. 7. Octyl gallate shows antifungal activity against Saccharomyces cerevisiae ATCC7754 and Zygosaccharomyces bailii ATCC 60483.

Undecanal exhibits inhibitory activity against Saccharomyces cerevisiae ATCC, Candida albicans, and fungi, and is widely used in biochemical experiments and drug synthesis research.

Apidaecin IB is an insect antimicrobial peptide, with MIC values of 8 μM for E. coli (O18K1H7, ML35 and ATCC 25922).

Apidaecin IB acetate is an insect antibacterial peptide. The minimum concentration of apidaecin IB acetate against Escherichia coli (E. coli ML35, o18k1h7 and ATCC 25922) is 8 μM.

Thiocillin I, a thiopeptide antibiotic, demonstrates potent in vitro antibacterial effects against Gram-positive bacteria. This compound exhibits minimum inhibitory concentrations (MICs) of 2 μg/mL, 0.5 μg/mL, 4 μg/mL, and 0.5 μg/mL against S. aureus 1974149, E. faecalis 1674621, B. subtilis ATCC 6633, and S. pyogenes 1744264, respectively.

CYP51-IN-20 (compound 5b), an antifungal agent, effectively inhibits CYP51 and exhibits significant activity against Candida albicans ATCC 10231. It suppresses the ERG11 (Cyp51) gene expression and markedly curtails the morphological transformation from yeast to hyphae. Furthermore, when combined with Voriconazole, CYP51-IN-20 synergistically occupies the entire CYP51 binding site, enhancing its inhibitory impact in the Glechoma moth model.

ATP synthase inhibitor3 (compound PT6) is an orally active inhibitor targeting the F-ATP synthase of Mycobacterium tuberculosis (IC50=0.788 μM). It effectively inhibits the growth of the Mycobacterium tuberculosis H37Rv strain (ATCC-27294) in vitro, depleting intracellular ATP levels at an IC50 of 30 μM.

Benzisothiazolone is an isothiazolinone fungicide that demonstrates growth inhibitory activity against Escherichia coli ATCC 8739 and yeast NCYC 1354. It is utilized in studies investigating growth inhibition models.

4-Hexen-3-one inhibits the growth of H. pylori in the ATCC 43526 strain and TDR strain. Additionally, this compound suppresses urease activity.

Antibacterialagent 256 (Compound C09) is an inhibitor of Type I signal peptidase (SPase I). It targets Gram-positive bacteria, effectively inhibiting S. aureus ATCC 29213, E. faecium QF31, E. faecalis SF23-1, and S. suis P1/7, with MIC values ranging from 1-16 μg/mL. In cancer cells HEp-2 and Caco-2, Antibacterialagent 256 exhibits cytotoxicity with CC50 values of 14.65 μg/mL and 21.93 μg/mL, respectively. Additionally, it shows hemolytic activity on mouse red blood cells with an HC50 of 13.29 μg/mL and can improve MRSA skin infections in mouse models.

DNA ligase-IN-2 (compound 2) acts as a potent LigA inhibitor, effectively hindering the DNA-independent spontaneous adenylation activity of full-length LigA and the truncated enzyme LigA:AD with an IC50 of 29 nM. It also significantly suppresses the in vitro growth of Staphylococcus aureus, showing MIC values of 1 μg/mL for S. aureus ATCC 29213 and S. aureus ATCC 700699, while the MIC for Escherichia coli (E. coli) ATCC 25922 is >64 μg/mL.

Antimicrobial agent-38 (compound 10) effectively inhibits methicillin-resistant Staphylococcus aureus (S. aureus) strain ATCC 700699 and non-resistant strain ATCC 29213, with minimum inhibitory concentrations (MIC) of 32 mg/L and 64 mg/L, respectively.

FtsZ-IN-12 (Compound 16e) is an inhibitor of filamentous temperature-sensitive mutant Z (FtsZ) that promotes the polymerization of the FtsZ protein and suppresses its GTPase activity, thus disrupting the bacterial cell division process. This compound exhibits broad-spectrum antibacterial activity, effectively inhibiting B. subtilis ATCC 9372, B. pumilus CMCC 63202, S. aureus ATCC 25923, E. coli BW25113, and A. baumannii ATCC 19606 with MIC values ranging from 0.062-1 µg/mL. Additionally, FtsZ-IN-12 can inhibit biofilm formation and eliminate mature biofilms. It possesses bactericidal properties and shows no hemolytic toxicity to mammalian red blood cells at a dosage of 15 mg/kg.

Antibacterialagent 274 (Compound 18b) is an antibacterial agent that targets bacterial cell membranes, exhibiting a minimum inhibitory concentration (MIC) of 8 μg/mL against Acinetobacter baumannii ATCC 17978. It functions by disrupting membrane integrity, causing intracellular accumulation of ROS, which leads to DNA and protein leakage, thereby exerting its antibacterial effects. Antibacterialagent 274 is applicable in research on infections caused by Gram-negative bacteria.

IPMCL-28b is an antimicrobial agent targeting bacterial cell membranes, with a minimum inhibitory concentration (MIC) of 1.56 μg/mL for Staphylococcus aureus ATCC 25923 and an MIC of 6.25 μg/mL for methicillin-resistant Staphylococcus aureus (MRSA). IPMCL-28b shows potential for research in the field of infection control.

PD-L1/LpxC-IN-1 (Compound 12b) is an inhibitor of PD-L1 and LpxC, with IC50 values of 5.2 μM and 0.081 μM, respectively. This compound disrupts bacterial lipopolysaccharide biosynthesis, leading to bacterial cell lysis and death. It effectively inhibits Gram-negative bacteria, exhibiting a minimum inhibitory concentration (MIC) of 0.25-0.5 μg/mL against K. pneumoniae ATCC 13883, E. coli ATCC 8739, S. typhimurium ATCC 14028, and P. aeruginosa ATCC 9027. Additionally, PD-L1/LpxC-IN-1 modulates the immune response by downregulating the expression of inflammatory cytokines IL-2 and IFN-γ, and upregulating CD4+ and CD8+ cells, thus activating the immune system and mitigating excessive inflammatory responses. In a mouse model of K. pneumoniae ATCC 13883 infection, PD-L1/LpxC-IN-1 demonstrated antibacterial activity.

hERG-IN-1 (compound 2a) acts as both an antimicrobial agent and an hERG inhibitor. It is effective in suppressing lung infections caused by Pseudomonas aeruginosa strain ATCC 27853.

Antibacterialagent 215 (Compound 3b) acts as an inhibitor of carbonic anhydrase (CA), with Ki values of 17.61, 5.14, and 43.74 nM for hCA I, hCA II, and AChE, respectively. It exhibits antitubercular activity with an MIC of 62.5 µg/ml against M. tuberculosis, and demonstrates antifungal potency against Candida spp. strains ATCC 14053, ATCC 1369, and ATCC 15126, with an MIC of 125 µg/ml.

Antibacterial agent 228 (Compound 8) inhibits mycobacterial ribosomes with an IC50 of 2.31 μM against Mycobacterium smegmatis. It demonstrates antibacterial activity with MIC values of 2 and 0.25 μg/mL against both wild-type and Δ1258c mutant strains of M. tuberculosis H37Rv, 8 μg/mL against wild-type and Δ2780c mutant strains of M. abscessus ATCC 19977, and 8 μg/mL against M. smegmatis.

Anti-MRSA agent 14 (Compound C17) exhibits antibacterial activity against MRSA and in a MRSA-infected mouse skin model. It demonstrates greater potential against MRSA compared to Norfloxacin. Anti-MRSA agent 14 disrupts cell membranes and inhibits metabolism. Its antibacterial MIC values against S. aureus ATCC 6538, S. aureus ATCC 29213, S. epidermidis ATCC 12228, and MRSA are 1, 2, 2, and 1 μM, respectively.